Article Fingerprint
ReserarchID
VIN78
The Bohring-Opitz syndrome (BOPS) was first described in 1999 by Bohring et al (1). It is an extremely rare genetic condition, of unknown prevalence, which is caused by de novo or nonsense mutations in the ASXL1 gene. To date 46 people with BOPS have been described, of whom only 20 have a confirmed molecular diagnosis. The BOPS diagnosis is established by clinical suspicion and / or identification of a constitutional heterozygous pathogenic variant in the ASXL1 gene (2). This article shows the first case in Latin America of BOPS confirmed by molecular diagnosis.
Daniela Alejandra Tolosa Quintero. 2019. \u201cBohring-Opitz Syndrome for the Purpose of a Case and Review of the Topic\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 19 (GJMR Volume 19 Issue F2): .
Crossref Journal DOI 10.17406/gjmra
Print ISSN 0975-5888
e-ISSN 2249-4618
Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.
Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.
Total Score: 103
Country: Colombia
Subject: Global Journal of Medical Research - F: Diseases
Authors: Daniela Alejandra Tolosa Quintero, Carolina Rivera Nieto, Juan Sebastián Leguizamón Melo (PhD/Dr. count: 0)
View Count (all-time): 132
Total Views (Real + Logic): 2855
Total Downloads (simulated): 1446
Publish Date: 2019 03, Fri
Monthly Totals (Real + Logic):
This paper attempted to assess the attitudes of students in
Advances in technology have created the potential for a new
Inclusion has become a priority on the global educational agenda,
The Bohring-Opitz syndrome (BOPS) was first described in 1999 by Bohring et al (1). It is an extremely rare genetic condition, of unknown prevalence, which is caused by de novo or nonsense mutations in the ASXL1 gene. To date 46 people with BOPS have been described, of whom only 20 have a confirmed molecular diagnosis. The BOPS diagnosis is established by clinical suspicion and / or identification of a constitutional heterozygous pathogenic variant in the ASXL1 gene (2). This article shows the first case in Latin America of BOPS confirmed by molecular diagnosis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.